Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia? - Wikidata - awgldk - TriplyDB

Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?

Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?

http://www.wikidata.org/entity/Q38182335

about

UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.Selective inhibition of the myeloid Src-family kinase Fgr potently suppresses AML cell growth in vitro and in vivo.

P2860

Q34104338-C8854AE7-1EFD-4B18-B433-1C63785B413F Q36876973-9F046810-6BF6-4461-9CF8-ECCF8926DD1B Q37037268-88E06D8C-1177-47B4-89EC-E069F839D0F0 Q37379680-09A0A25D-B13F-4BE1-B860-E633DFC0B2F1 Q38245417-62833939-9789-471F-9856-81E0131907C4 Q38285175-BEB42109-C06D-4A7B-9849-D8D465718D24 Q42363757-E4D3AA01-50DE-4EC2-8D73-C086B20061F0 Q46300745-68F23C58-6422-4F02-BBA0-B90928BF401D Q46406409-043C8AC2-2B20-4E11-9E75-BA01AD746E87 Q49207324-1D1CE45D-23B3-41FC-902E-4BB3C6310AE3 Q54109758-BDDE24E0-5C91-4205-A230-0B949EF5A69B

P2860

Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?

http://www.wikidata.org/entity/Q38182335

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?

@en

type

label

Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?

@en

prefLabel

Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?

@en

P1433

Q38182335-ADF4C1B9-BB58-4650-A947-87393233EE3F

P1476

Q38182335-83475BE4-CAEF-484A-A274-A5DD0AE0ED6C

P2093

Q38182335-5514CC2B-7969-4102-B2E1-8CE1D9400D6D

Q38182335-8581D5F2-2F0B-4ED3-8C6F-30AEF927DBEA

P2860

Q38182335-056E08C7-A635-4BF1-B9E1-E3028DE0B325

Q38182335-12C119A0-483D-4624-AA23-786C5982FA25

Q38182335-18E5EF8D-70C2-4E91-9129-9BEBC6D72C78

Q38182335-23675A40-D97A-4AE8-8C42-2507EF00BDB5

Q38182335-288C283C-541A-4641-A009-D7C5280FFAC4

Q38182335-2C11F44D-8DAD-4B9B-9135-3EAE6778D15B

Q38182335-2EE7D054-7820-424D-A974-B369CDECEFC7

Q38182335-358707C7-251F-4F1A-855A-EEE28ED868F5

Q38182335-39A9F74C-DD94-44F8-ADF1-78363EDEEB91

Q38182335-3C3CB0FD-E683-444E-94EB-8D886FE5B36F

P304

Q38182335-18B25530-4E96-444E-9A0E-A212C0A4BA63

P31

Q38182335-FFACC819-297D-40BB-A999-867451726C92

P356

Q38182335-DE79F56A-8979-400B-A5EC-BF5E10352CB1

P433

Q38182335-0C81F285-DCFD-4FB0-9491-55649A235FE6

P478

Q38182335-4A0EE31C-0665-4EFB-B684-FC2DC3DEC291

P577

Q38182335-FEB082E9-C133-4312-B053-44C7DD97035B

P698

Q38182335-C70DCD6B-0586-49A3-9AD8-2A1D4CFD88B0

P932

Q38182335-25C2DC9B-3A93-44C5-A7B5-F08A84679A0E

P356

MOH.0000000000000022

P1433

Current Opinion in Hematology

P1476

Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?

@en

P2093

Keith W Pratz

http://www.w3.org/2001/XMLSchema#string

Selina M Luger

http://www.w3.org/2001/XMLSchema#string

P2860

STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.

FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

P304

72-78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MOH.0000000000000022

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24468836

http://www.w3.org/2001/XMLSchema#string

P932

4142569

http://www.w3.org/2001/XMLSchema#string